Wim Verlinden

Wim Verlinden


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2016 in Journal of Ultrasound in Medicine
Verified
Journal Article
Closed access
PDF file
WVWim Verlinden
Wim Verlinden
SBStefan Bourgeois
Stefan Bourgeois
PGPierre Gigase
Pierre Gigase
CTClara Thienpont
Clara Thienpont
LVLuisa Vonghia
Luisa Vonghia
SFSven Francque
Sven Francque

1 December 2015
Verified
Journal Article
Closed access
WVWim Verlinden
Wim Verlinden
SBStefan Bourgeois
Stefan Bourgeois
MMMarc De Maeyer
Marc De Maeyer
LVLuisa Vonghia
Luisa Vonghia
TVThomas Vanwolleghem
Thomas Vanwolleghem
SFSven Francque
Sven Francque

27 November 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
WVWim Verlinden
Wim Verlinden
EMEugénie Van Mieghem
Eugénie Van Mieghem
LDLaura Depauw
Laura Depauw
TVThomas Vanwolleghem
Thomas Vanwolleghem
LVLuisa Vonghia
Luisa Vonghia
SFSven M Francque
Sven M Francque
The incidence of non-alcoholic fatty liver disease (NAFLD) is rising across the globe, with the presence of steatohepatitis leading to a more aggressive clinical course. Currently, the diagnosis of non-alcoholic steatohepatitis (NASH) is based on histology, though with the high prevalence of NAFLD, a non-invasive method is needed. The 13C-aminopyrine breath test (ABT) evaluates the microsomal liver function and could be a potential candidate. We aimed to evaluate a potential change in liver function in NASH patients and to evaluate the diagnostic power of ABT to detect NASH. We performed a retrospective analysis on patients suspected of NAFLD who underwent a liver biopsy and ABT. 440 patients were included. ABT did not decrease in patients with isolated liver steatosis but decreased significantly in the presence of NASH without fibrosis and decreased even further with the presence of significant fibrosis. The predictive power of ABT as a single test for NASH was low but improved in combination with ALT and ultrasonographic steatosis. We conclude that microsomal liver function of patients with NASH is significantly decreased, even in the absence of fibrosis. The ABT is thus a valuable tool in assessing the presence of NASH; and could be used as a supplementary diagnostic tool in clinical practice.